Press Releases

AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

John Whyte, MD, MPH, interview at MATTER

AMA CEO: AI is not medicine’s future—“this is happening now.”

| 6 Min Read
Health care professionals about to begin a telehealth appointment

Practice ownership linked to physicians’ use of telehealth

| 5 Min Read
Pharmacist filling prescription

Investigating pharmacists’ refusal to fill valid physician orders

| 6 Min Read
Moving Medicine-Sutton and Bacher

CMS launches modernized physician ACO model

| 6 Min Read